Market Research Report
Male Health Drug Development Pipeline Review, 2017
|Published by||GlobalData||Product code||564939|
|Published||Content info||125 Pages
Delivery time: 1-2 business days
|Male Health Drug Development Pipeline Review, 2017|
|Published: September 25, 2017||Content info: 125 Pages||
Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of 23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.
Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.
Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.
The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.
The report, "Male Health Drug Development Pipeline Review, 2017" provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.